EAG Laboratories to Present “ADC Development: Keys to Rapid Investigational New Drug Submission and Approval” at BioPharma Asia 2017
Columbia, Missouri – March 13, 2017 – EAG Laboratories, a global scientific services company that provides testing, analytical and characterization services to technology- and life-science-related industries, announced that Glenn Petrie, Ph.D., EAG Laboratories’ Senior Scientific Advisor specializing in biopharmaceutical development, will participate in an upcoming seminar presentation at BioPharma Asia 2017, hosted in Singapore later this month. The seminar entitled, “ADC Development: Keys to Rapid IND Submission and Approval,” will be presented on March 22 at 1:00 p.m., at the Suntec Singapore convention center.
During the presentation, Dr. Petrie will discuss the unique analytical challenges presented by the complex structure of antibody drug conjugates (ADCs) and the myriad of analyses required in support of a successful investigational new drug application (IND). If these unique issues are not addressed correctly or in a timely fashion, they can cause delays in submission and even rejection of the IND, based upon a lack of proper data.
EAG has extensive experience and expertise supporting successful INDs in an accelerated time frame. This presentation will also highlight proven ways to maximize the probability of a successful IND, while minimizing the time and effort required. Topics include critical biopharmaceutical characterization parameters such as tertiary structure, charge variants and critical quality attributes (CQA), as well as studies that may be frequently overlooked, such as compatibility and residual solvents.
With over 20 years of experience in support of biotechnology projects, Dr. Petrie helps EAG Laboratories’ clients answer challenging development questions unique to large molecule development. He serves as the primary business development contact for EAG Laboratories’ biopharmaceutical development projects. Dr. Petrie earned his Ph.D. in biochemistry at the University of Illinois Urbana-Champaign, and performed post-doctoral studies at the Mayo School of Health Sciences.
For additional information, visit http://www.eag.com/biopharmaceuticals/
About EAG Laboratories:
EAG Laboratories is a global scientific services company serving clients across a vast array of technology-related industries. Through multidisciplinary expertise in the life, materials and engineering sciences, EAG helps companies innovate and improve products, ensure quality and safety, protect intellectual property, and comply with evolving global regulations. EAG employs 1,200+ employees in seven countries, across 20 laboratories serving more than 4,000 clients worldwide.
EAG Laboratories is a trade name of EAG Inc., majority owned by Odyssey Investment Partners LLC, a leading private equity firm with more than $3.5 billion in capital under management. Odyssey makes majority, control investments primarily in established middle-market industrial manufacturing and business services companies in a variety of industries. Further information regarding Odyssey Investment Partners can be found at www.odysseyinvestment.com.
Company contact: Kristein King VP, Marketing & Communications EAG Laboratories e: firstname.lastname@example.org t: +1-573-777-6209
Agency contact: David Richardson Managing Partner Impress Labs e: email@example.com t: +1-415-994-1423